Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
British Journal of Cancer|June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaM E Gore, C Szczylik, C Porta, et al.
ESMO Open|December 5, 2021
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinomaR Kanesvaran, C Porta, A Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trialT K Choueiri, L Albigès, D F McDermott, et al.
ESMO Open|December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access ProgramS E Rebuzzi, A Signori, S Buti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialN M Tannir, L Albigès, D F McDermott, et al.
ESMO Open|December 5, 2023
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patientsL Arenare, C Porta, D Barberio, et al.
Journal of Cancer Policy|October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patientsL Arenare, C Porta, D Barberio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumoursK S Saini, M Koopman, D Martins-Branco, et al.
Pageof 19